SCHEMBL23923918

SCHEMBL23923918

O=C(NC1CNCC1c1ccccc1)c1cccc2cnccc12

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 3/20 0.50
CNR1 P21554 3/20 0.43
CNR2 P34972 2/20 0.43
SSTR4 P31391 2/20 0.43
PREP P48147 2/20 0.43
DPP7 Q9UHL4 1/20 0.43
MAPK1 P28482 5/20 0.42
TRPV1 Q8NER1 2/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23951813 1.00 ROCK2 (0.50) ROCK2CNR1CNR2SSTR4PREP
SCHEMBL30114348 1.00 ROCK2 (0.50) ROCK2CNR1CNR2SSTR4PREP
SCHEMBL23951291 0.84 CNR1 (0.50) CNR1CNR2SSTR4PREPDPP7
SCHEMBL23951503 0.82 BACE1 (0.44) ROCK2CNR1CNR2SSTR4PREP
SCHEMBL23951260 0.82 BACE1 (0.44) ROCK2CNR1CNR2SSTR4PREP
Hydrochloric Acid SCHEMBL29900745 0.81 BACE1 (0.43) ROCK2CNR1CNR2SSTR4PREP
Hydrochloric Acid SCHEMBL23924329 0.81 BACE1 (0.43) ROCK2CNR1CNR2SSTR4PREP
SCHEMBL23923789 0.80 ALDH1A1 (0.53) MAPK1KMT2AMEN1HTTBLM
SCHEMBL23951372 0.80 ALDH1A1 (0.53) MAPK1KMT2AMEN1HTTBLM
SCHEMBL23951469 0.77 PRKD3 (0.46) ROCK2MAPK1KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US claimed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US claimed
EP-4110758-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 Tes Pharma S.r.l. (IT) 2023-01-04 EP disclosed
CN-115427394-A Heterocyclic compounds for modulating NR2F6 TES制药有限责任公司 2022-12-02 CN disclosed
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 ROCK2 2207/4885CNR1 1610/4885CNR2 1390/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 ROCK2 2207/4885CNR1 1610/4885CNR2 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.